The study for surgical outcome of trabeculectomy for neovascular glaucomatous patients who received an additional bevacizumab treatment after the surgery.

The study for surgical outcome of trabeculectomy for neovascular glaucomatous patients who received an additional bevacizumab treatment after the surgery. - Surgical outcome in neovascular glaucomatous patients with bevacizumab after trabeculectomy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000895

Enrollment

Registered

2007-11-19

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with neovascular glaucoma

Interventions

Patients are treated with an intravitreal injection of 1.25 mg bevacizumab (avastin) within 5 days before trabeculectomy, then treated with trabeculectomy. Then, they are treated with an intravitreal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with neovascular glaucoma. Intraocular pressure levels of higher than 21 mmHg before trabeculectomy.

Exclusion criteria

Exclusion criteria: Patients who have been previously treated with trabeculectomy. Patients who had been treated with bevacizumab within recent 2 months.

Design outcomes

Primary

Measure	Time frame
Intraocular pressure levels after an additional treatment of bevacizumab following trabeculectomy.	—

Secondary

Measure	Time frame
The size of filtrating bleb. The inflammation in the anterior chamber The concentrations of cytokines in the anterior chamber.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026